Lupin & SteinCares Biosimilar Deal

  Published 1 year ago

Lupin partnered with SteinCares to commercialize its ranibizumab biosimilar throughout Latin America (excluding Mexico & Argentina). SteinCares will manage regulatory & commercial aspects, while Lupin handles manufacturing.

  • SteinCares leads LATAM commercialization.
  • Lupin manufactures ranibizumab.
  • Ranibizumab treats various retinal conditions.

You might like these

Nifty Futures Close Slightly Above Spot

India's IIP Grows 1.5% in June 2025

Cummins India Launches BESS for Sustainable Energy Future

Mutual Fund Inflows Hit New High

Hindustan Copper-Coal India Sign MoU for Mineral Collaboration

Sula Revenue Stable, Profit Falls

India's Power Capacity Soars 90% to 475 GW in a Decade

News that matters the most ⚡